AbbVie Inc (ABBV)vsHims Hers Health Inc (HIMS)
ABBV
AbbVie Inc
$198.71
-1.11%
HEALTHCARE · Cap: $354.64B
HIMS
Hims Hers Health Inc
$30.56
+8.56%
HEALTHCARE · Cap: $6.78B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2505% more annual revenue ($61.16B vs $2.35B). ABBV leads profitability with a 6.9% profit margin vs 5.5%. ABBV appears more attractively valued with a PEG of 0.47. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
HIMS
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-21.7%
Fair Value
$163.28
Current Price
$198.71
$35.43 premium
Margin of Safety
+24.9%
Fair Value
$39.63
Current Price
$30.56
$9.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Every $100 of equity generates 25 in profit
Revenue surging 28.4% year-over-year
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Trading at 12.8x book value
Distress zone — elevated risk
5.5% margin — thin
Operating margin of 2.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.47 suggests the stock is reasonably priced for its growth.
Bull Case : HIMS
The strongest argument for HIMS centers on Return on Equity, Revenue Growth. Revenue growth of 28.4% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 84.6x leaves little room for execution misses.
Bear Case : HIMS
The primary concerns for HIMS are Price/Book, Altman Z-Score, Profit Margin. A P/E of 58.4x leaves little room for execution misses. Debt-to-equity of 2.34 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while HIMS is a growth play — different risk/reward profiles.
HIMS carries more volatility with a beta of 2.31 — expect wider price swings.
HIMS is growing revenue faster at 28.4% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 50/100). HIMS offers better value entry with a 24.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Hims Hers Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?